E-LIB Suche - Ergebnisse für: Stalman, Eileen W. - Sprache DE

Personensuche X

Sortierung: Relevanz

Sortierung: Jahr

1

Suppressed IgG4 class switching in dupilumab‐ and TNF inhib..:

Valk, Anika M. ; Keijser, Jim B. D. ; van Dam, Koos P. J....
Allergy. , 2024

Link: https://doi.org/10.1111/..

2

Longitudinal rheumatoid factor autoantibody responses after..:

Keijzer, Sofie ; Oskam, Nienke ; Ooijevaar-de Heer, Pleuni...
Frontiers in Immunology. 15 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

3

mRNA-1273 vaccinated inflammatory bowel disease patients re..:

van den Dijssel, Jet ; Duurland, Mariël C. ; Konijn, Veronique AL....
Journal of Autoimmunity. 144 (2024) - p. 103175 , 2024

Link: https://doi.org/10.1016/..

4

T cell activation markers CD38 and HLA-DR indicative of non..:

Verstegen, Niels J M ; Hagen, Ruth R ; Kreher, Christine...
Journal of Neurology, Neurosurgery & Psychiatry. , 2024

Link: https://doi.org/10.1136/..

5

Clinical and humoral responses after SARS-CoV-2 breakthroug..:

Stalman, Eileen W. ; Wieske, Luuk ; Keijser, Jim B.D....
Journal of Allergy and Clinical Immunology. , 2024

Link: https://doi.org/10.1016/..

6

Disease activity in patients with immune-mediated inflammat..:

van Dam, Koos P.J. ; Wieske, Luuk ; Stalman, Eileen W....
Journal of Autoimmunity. 135 (2023) - p. 102984 , 2023

Link: https://doi.org/10.1016/..

7

Primary SARS-CoV-2 infection in patients with immune-mediat..:

van Dam, Koos P. J. ; Volkers, Adriaan G. ; Wieske, Luuk...
BMC Infectious Diseases. 23 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

8

Longitudinal increase of humoral responses after four SARS-..:

van Kempen, Zoé LE ; van Dam, Koos PJ ; Keijser, Jim BD...
Multiple Sclerosis Journal. 30 (2023) 3 - p. 443-447 , 2023

Link: https://doi.org/10.1177/..

9

Longitudinal SARS-CoV-2 humoral response in MS patients wit..:

van Dam, Koos P. J. ; Hogenboom, Laura ; Stalman, Eileen W....
Frontiers in Neurology. 13 (2022) - p. , 2022

Link: https://doi.org/10.3389/..

10

Humoral responses after second and third SARS-CoV-2 vaccina..:

Wieske, Luuk ; van Dam, Koos P J ; Steenhuis, Maurice...
The Lancet Rheumatology. 4 (2022) 5 - p. e338-e350 , 2022

Link: https://doi.org/10.1016/..

11

Risk factors associated with short-term adverse events afte..:

Wieske, Luuk ; Kummer, Laura Y. L. ; van Dam, Koos P. J....
BMC Medicine. 20 (2022) 1 - p. , 2022

Link: https://doi.org/10.1186/..

12

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2..:

van Kempen, Zoé L. E. ; Hogenboom, Laura ; Toorop, Alyssa A....
Annals of Neurology. 93 (2022) 1 - p. 103-108 , 2022

Link: https://doi.org/10.1002/..

13

Antibody development and disease severity of COVID-19 in no..:

Boekel, Laura ; Hooijberg, Femke ; Vogelzang, Erik H...
RMD Open. 8 (2022) 1 - p. e002035 , 2022

Link: https://doi.org/10.1136/..

14

Immune dynamics in SARS-CoV-2 experienced immunosuppressed ..:

Verstegen, Niels JM ; Hagen, Ruth R ; van den Dijssel, Jet...
eLife. 11 (2022) - p. , 2022

Link: https://doi.org/10.7554/..

15

Primary SARS-CoV-2 infection in patients with immune-mediat..:

van Dam, Koos P. J ; Volkers, Adriaan G ; Wieske, Luuk...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189216/. , 2023

Link: http://www.ncbi.nlm.nih...

1-15